目的 研究柳氮磺吡啶联合地衣芽孢杆菌对溃疡性结肠炎的疗效及其对血清炎症因子水平的影响。方法 选择2017年8月—2018年8月杨凌示范区医院收治的82例溃疡性结肠炎患者作为研究对象，根据入院的顺序将患者用抽签法随机分为对照组和观察组，每组各41例。对照组患者口服地衣芽孢杆菌活菌胶囊，0.5 g/次，3次/d。观察组在对照组的基础上联合口服柳氮磺吡啶肠溶片，6片/次，3次/d。两组均连续治疗12周。观察两组患者的临床疗效，同时比较两组患者的症状改善时间、临床疾病活动指数（CAI）和血清炎症因子水平。结果 治疗后，观察组的总有效率为90.24%，明显高于对照组的70.73%（P<0.05）。治疗后，两组患者的CAI评分均显著降低（P<0.05）；观察组的CAI评分、腹泻消失时间和血便消失时间明显低于对照组（P<0.05）。两组治疗后的肠黏膜Toll样受体4（TLR-4）和血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平均明显降低（P<0.05），且观察组上述指标明显低于对照组（P<0.05）。结论 柳氮磺吡啶联合地衣芽孢杆菌能改善溃疡性结肠炎患者的炎症水平，安全有效，值得进一步研究。

Objective To study the effect of sulfasalazine combined with bacillus licheniformis in treatment of ulcerative colitis and its effect on the level of serum inflammatory factors. Methods A total of 82 patients with ulcerative colitis admitted to Yangling Demonstration Zone Hospital from August 2017 to August 2018 were selected as the study subjects. According to the order of admission, the patients were randomly divided into control group and observation group by lottery, with 41 patients in each group. Patients in the control group were po administered with Bacillus Licheniformis Capsule, Live, 0.5 g/time, three times daily. Patients in the observation group were po administered with Sulfasalazine Enteric-coated Tablets on the basis of control group, 6 tablets/time, three times daily. Both groups were treated continuously for 12 weeks. The clinical efficacy in two groups was observed, and symptom improvement time, clinical disease activity index (CAI), and serum inflammatory factors between two groups were compared. Results After treatment, the total effective rate in the observation group was 90.24%, which was significantly higher than 70.73% in the control group (P<0.05). After treatment, CAI scores in two groups were significantly reduced (P<0.05). And CAI score, vanishing time of diarrhea and vanishing time of blood stool in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the levels of TLR-4, TNF-α, and IL-6 in the intestinal mucosa of two groups were significantly decreased (P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Sulfasalazine combined with bacillus licheniformis can improve the inflammation level in patients with ulcerative colitis, which is safe and effective and worthy of further study.

R975